Study of GL701 in Men With Systemic Lupus Erythematosus

Inclusion Criteria * Patient must have a diagnosis of SLE \> 6 months according to the 1989 revised ACR criteria. Patient must meet at least four of the eleven ACR criteria for systemic lupus * Patient must have a modified SLEDAI score \> 3 at both screening and qualifying visits (Appendix A-2) * Patient must be treated for SLE with doses of prednisone \< 30 mg/day (including those on NO glucocorticoid therapy) unchanged for \> 6 weeks prior to study entry (including both screening and qualifying visits). Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose * Patient treated with azathioprine, methotrexate, or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study * Patient must be able to read and speak English and willing to sign an informed consent in English Exclusion Criteria * Patient with a history of prostate cancer * Patient with elevated Prostate Specific Antigen (PSA) * Patient diagnosed with liver disease, defined as AST or ALT \> 3x the upper limit of normal * Patient ingesting body building/anabolic steroids within the last 6 months preceding the study * Patient with end stage renal disease or receiving hemodialysis treatment * Patient with serum creatinine \> 2 mg/dl or creatinine clearance \< 60 ml/min * Patient receiving treatment with ACTH within the 3 months preceding study entry * Patient receiving androgens, immunoglobulins, cyclophosphamide, cyclosporin A, or other immunosuppressive agents, except azathioprine, methotrexate, and hydrochloroquine within the last 3 months * Patient with known hypersensitivity to DHEA or the inactive ingredients used in the GL70l formulation (cornstarch, lactose, and magnesium stearate) * Patient who participated in any prior DHEA study or administration of DHEA within the past 3 months * Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent * Patient with any condition which in the Investigator's or sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g.. alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease) * Patient requires treatment/medication prohibited by protocol * Patient with any serious EKG abnormality as determined by the Investigator